JP2018524292A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524292A5
JP2018524292A5 JP2017562988A JP2017562988A JP2018524292A5 JP 2018524292 A5 JP2018524292 A5 JP 2018524292A5 JP 2017562988 A JP2017562988 A JP 2017562988A JP 2017562988 A JP2017562988 A JP 2017562988A JP 2018524292 A5 JP2018524292 A5 JP 2018524292A5
Authority
JP
Japan
Prior art keywords
day
cancer
combination according
platin
pyrimido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017562988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524292A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/043041 external-priority patent/WO2017015316A1/en
Publication of JP2018524292A publication Critical patent/JP2018524292A/ja
Publication of JP2018524292A5 publication Critical patent/JP2018524292A5/ja
Pending legal-status Critical Current

Links

JP2017562988A 2015-07-21 2016-07-20 オーロラキナーゼインヒビターと化学療法剤の投与 Pending JP2018524292A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195103P 2015-07-21 2015-07-21
US62/195,103 2015-07-21
PCT/US2016/043041 WO2017015316A1 (en) 2015-07-21 2016-07-20 Administration of aurora kinase inhibitor and chemotherapeutic agents

Publications (2)

Publication Number Publication Date
JP2018524292A JP2018524292A (ja) 2018-08-30
JP2018524292A5 true JP2018524292A5 (enExample) 2019-08-15

Family

ID=57834580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017562988A Pending JP2018524292A (ja) 2015-07-21 2016-07-20 オーロラキナーゼインヒビターと化学療法剤の投与

Country Status (4)

Country Link
US (3) US20180207173A1 (enExample)
EP (1) EP3324976A4 (enExample)
JP (1) JP2018524292A (enExample)
WO (1) WO2017015316A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. オーロラキナーゼインヒビターと化学療法剤の投与

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1084747C (zh) 1996-03-08 2002-05-15 曾尼卡有限公司 作为神经活性剂的吡咯并苯并氮杂䓬衍生物
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式2−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CN1155599C (zh) 1997-09-29 2004-06-30 明治制果株式会社 三环三唑并苯并氮杂�衍生物、用于制备该衍生物的方法和抗变态反应剂
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
BR0211729A (pt) 2001-08-09 2004-08-24 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
PT1578755E (pt) 2002-12-24 2007-10-19 Astrazeneca Ab Derivados de fosfonooxiquinazolina e sua utilização farmacêutica
US20060264493A1 (en) 2003-02-17 2006-11-23 Ermes Vanotti Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315657D0 (en) 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ES2299080T3 (es) 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
JP4812763B2 (ja) 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ, インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
JP2008505167A (ja) 2004-07-05 2008-02-21 アステックス、セラピューティックス、リミテッド 医薬組成物
ATE485300T1 (de) 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
DK1812581T3 (da) 2004-11-15 2009-05-11 Rigel Pharmaceuticals Inc Fremgangsmåde til fremstilling af optisk aktive N-carbamat-beskyttede beta-lactamer ved optisk oplösning under anvendelse af en candida antarctica lipase
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US20080312223A1 (en) 2004-12-30 2008-12-18 Astex Therapeutics Limited Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2006070202A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
US7485661B2 (en) 2005-01-18 2009-02-03 Pfizer Italia S.R.L. Heterobicyclic pyrazole derivatives as kinase inhibitors
ES2535854T3 (es) 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
CN101316597B (zh) 2005-11-03 2013-04-17 顶点医药品公司 用作激酶抑制剂的氨基嘧啶
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
TW200808311A (en) 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2007129062A1 (en) 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
WO2007132221A1 (en) 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
WO2007132220A1 (en) 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
GB0609530D0 (en) 2006-05-12 2006-06-21 Cyclacel Ltd Combination
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2009114703A2 (en) 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
UY34114A (es) * 2011-06-03 2013-01-03 Millennium Pharm Inc Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. オーロラキナーゼインヒビターと化学療法剤の投与

Similar Documents

Publication Publication Date Title
ES2964764T3 (es) Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino
RU2605335C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2019515908A5 (enExample)
JP2010270124A5 (enExample)
JP2016515628A5 (enExample)
JP2019536805A5 (enExample)
JP2006515883A5 (enExample)
JP2013507415A5 (enExample)
JP2012255026A5 (enExample)
JP2016539156A5 (enExample)
ES2625492T3 (es) Combinación terapéutica que comprende un inhibidor de Cdc7 y un agente antineoplásico
JP2014513123A5 (enExample)
CN103533940A (zh) 治疗晚期实体瘤的方法
JP2017533220A5 (enExample)
JP2008514577A5 (enExample)
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
Lee et al. S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer: results from the randomized phase III POST trial
MX2014002663A (es) Nuevo esquema de administracion de la n-hidroxi-4-{2-[3-(n,n-dimet ilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida.
JP2018519300A5 (enExample)
JP2019513812A5 (enExample)
JP2019517507A5 (enExample)
JP2014148552A5 (enExample)
JP2021505669A5 (enExample)
JP2018524292A5 (enExample)
JP2020520385A5 (enExample)